This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by de Jong, M. C. Articles by Scheper, R. J. Search for Related Content PubMed PubMed Citation Articles by de Jong, M. C. Articles by Scheper, R. J.

Peptide Transport by the Multidrug Resistance Protein MRP1¹

Department of Pathology [M. C. d. J., G. L. S., A. B. S., R. J. S.] and Medical Oncology [H. J. B.], University Hospital Vrije Universiteit, 1081 HV Amsterdam; Department of Molecular Recognition, Institute for Animal Science and Health (ID-DLO), 8200 AB Lelystad [J. W. S., W. C. P., R. D., R. H. M.]; and Division of Molecular Biology, The Netherlands Cancer Institute, 1066 CX Amsterdam [M. K.], the Netherlands

Small hydrophobic peptides were studied as possible substrates of the multidrug resistance protein (MRP)-1 (ABCC1) transmembrane transporter molecule. As observed earlier for P-glycoprotein- (Pgp; ABCB1) overexpressing cells, MRP1-overexpressing cells, including cells stably transfected with the MRP1 cDNA, showed distinct resistance to the cytotoxic peptide N-acetyl-Leu-Leu-norleucinal (ALLN). Resistance to this peptide and another toxic peptide derivative, which is based on a Thr-His-Thr-Nle-Glu-Gly backbone conjugated to butyl and benzyl groups (4A6), could be reversed by MRP1 inhibitors. The reduced toxicity of 4A6 in MRP1-overexpressing cells was found to be associated with lower accumulation of a fluorescein-labeled derivative of this peptide. Glutathione (GSH) depletion had a clear effect on resistance to ALLN but hardly affected 4A6 resistance. In a limited structure-activity study using peptides that are analogous to 4A6, MRP1-overexpressing cells were found to be resistant to these peptides as well. Remarkably, when selecting A2780 ovarian cancer cells for resistance to ALLN, even in the absence of Pgp blockers, resulting cell lines had up-regulated MRP1, rather than any of the other currently known multidrug resistance transporter molecules including Pgp, MRP2 (ABCC2), MRP3 (ABCC3), MRP5 (ABCC5), and the breast cancer resistance protein ABCG2. ALLN-resistant, MRP1-overexpressing cells were found to be cross-resistant to 4A6 and the classical multidrug resistance drugs doxorubicin, vincristine, and etoposide. This establishes MRP1 as a transporter for small hydrophobic peptides. More extensive structure-activity relationship studies should allow the identification of clinically useful peptide antagonists of MRP1.

This article has been cited by other articles:

				R. Oerlemans, N. E. Franke, Y. G. Assaraf, J. Cloos, I. van Zantwijk, C. R. Berkers, G. L. Scheffer, K. Debipersad, K. Vojtekova, C. Lemos, et al. Molecular basis of bortezomib resistance: proteasome subunit {beta}5 (PSMB5) gene mutation and overexpression of PSMB5 protein Blood, September 15, 2008; 112(6): 2489 - 2499. [Abstract] [Full Text] [PDF]

				C. D. Klaassen and H. Lu Xenobiotic Transporters: Ascribing Function from Gene Knockout and Mutation Studies Toxicol. Sci., February 1, 2008; 101(2): 186 - 196. [Abstract] [Full Text] [PDF]

				R. G. Deeley, C. Westlake, and S. P. C. Cole Transmembrane Transport of Endo- and Xenobiotics by Mammalian ATP-Binding Cassette Multidrug Resistance Proteins. Physiol Rev, July 1, 2006; 86(3): 849 - 899. [Abstract] [Full Text] [PDF]

				A. Haimeur, G. Conseil, R. G. Deeley, and S. P.C. Cole Mutations of Charged Amino Acids in or near the Transmembrane Helices of the Second Membrane Spanning Domain Differentially Affect the Substrate Specificity and Transport Activity of the Multidrug Resistance Protein MRP1 (ABCC1) Mol. Pharmacol., June 1, 2004; 65(6): 1375 - 1385. [Abstract] [Full Text] [PDF]

				M. C. de Jong, G. L. Scheffer, H. J. Broxterman, J. H. Hooijberg, J. W. Slootstra, R. H. Meloen, R. J. Kreitman, S. R. Husain, B. H. Joshi, R. K. Puri, et al. Multidrug-Resistant Tumor Cells Remain Sensitive to a Recombinant Interleukin-4-Pseudomonas Exotoxin, Except When Overexpressing the Multidrug Resistance Protein MRP1 Clin. Cancer Res., October 15, 2003; 9(13): 5009 - 5017. [Abstract] [Full Text] [PDF]

				J. Savolainen, J. E. Edwards, M. E. Morgan, P. J. McNamara, and B. D. Anderson Effects of a P-Glycoprotein Inhibitor on Brain and Plasma Concentrations of Anti-Human Immunodeficiency Virus Drugs Administered in Combination in Rats Drug Metab. Dispos., May 1, 2002; 30(5): 479 - 482. [Abstract] [Full Text] [PDF]